VXA-G1.1-NN
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for VXA-G1.1-NN, covering 2018-05-30 to 2024-06-21. Get the full timeline:
Most recent: Clinical Trial Update: A Phase 1, Open-label, Safety and Immunogenicity Study of an Oral Multi-dose Administration Regimen With an Adenoviral-vector Based Tablet Norovirus Vaccine (VXA-G1.1-NN) Administered to Healthy Adult Volunteers [Phase 1]